LYN

ENSG00000254087
Target class
Kinase
Chromosome
8
Approved drugs
2
Clinical candidates (approved and in development)
9

Approved drugs
2
Clinical candidates (approved and in development)
9

Chemical probe available
Yes

Other names
  • JTK8
Target name
LYN
Gene name
LYN proto-oncogene, Src family tyrosine kinase
Gene symbol
LYN
Protein name
Tyrosine-protein kinase Lyn (EC 2.7.10.2) (Lck/Yes-related novel protein tyrosine kinase) (V-yes-1 Yamaguchi sarcoma viral related oncogene homolog) (p53Lyn) (p56Lyn)

Gene biotype
Protein coding
Gene family
SH2 domain containing|Src family tyrosine kinases
Target class
Kinase
Target type
Human gene

Tissues expressed in
53
Protein localisation evidence grade
Supported
Highest tissue expression
128.38
Tissue specificity (Gini)
0.637
Tissue specificity (tau)
0.925

KEGG gene identifiers
  • hsa:4067
Protein interaction confidence
0.871669
Protein interaction partners
130

  • R-HSA-114604
  • R-HSA-1433557
  • R-HSA-1433559
  • R-HSA-202733
  • R-HSA-2029481
  • R-HSA-210990
  • R-HSA-2454202
  • R-HSA-2682334
  • R-HSA-2730905
  • R-HSA-2871796
  • R-HSA-2871809
  • R-HSA-2871837
  • R-HSA-389356
  • R-HSA-389513
  • R-HSA-3928662
  • R-HSA-3928663
  • R-HSA-3928665
  • R-HSA-5621480
  • R-HSA-5621575
  • R-HSA-5690714
  • R-HSA-69231
  • R-HSA-75892
  • R-HSA-9006335
  • R-HSA-9027276
  • R-HSA-9027277

And 12 more, listed on the interactive page.

End position
56014169
Start position
55879825
Chromosome
8
Strand
Forward

Ensembl gene ID
ENSG00000254087
HGNC ID
HGNC:6735
www.genenames.org
NCBI Gene ID
4067
UniProt ID
P07948

  • Cell membrane. Nucleus. Cytoplasm. Cytoplasm, perinuclear region. Golgi apparatus. Membrane
  • Lipid-anchor . Note=Accumulates in the nucleus by inhibition of CRM1-mediated nuclear export. Nuclear accumulation is increased by inhibition of its kinase activity. The trafficking from the Golgi apparatus to the plasma membrane occurs in a kinase domain-dependent but kinase activity independent manner and is mediated by exocytic vesicular transport. Detected on plasma membrane lipid rafts.
  • Golgi apparatus
  • Plasma membrane
  • Vesicles

Tissue specificity (tau)
0.925244
Expression inequality (Gini)
0.636792

Expression in transcripts per million

Whole Blood
128.38
Cells - EBV-transformed lymphocytes
119.31
Spleen
74.33
Lung
33.99
Small Intestine - Terminal Ileum
16.57

Expression in transcripts per million

  • Whole Blood128.38
  • Cells - EBV-transformed lymphocytes119.31
  • Spleen74.33
  • Lung33.99
  • Small Intestine - Terminal Ileum16.57
  • Minor Salivary Gland14.36
  • Thyroid13.68
  • Brain - Cerebellar Hemisphere12.34
  • Adipose - Visceral (Omentum)10.87
  • Adipose - Subcutaneous10.56
  • Brain - Cerebellum10.17
  • Breast - Mammary Tissue9.98
  • Bladder8.29
  • Artery - Coronary8.17
  • Cervix - Endocervix7.94
  • Artery - Aorta7.92
  • Vagina7.52
  • Fallopian Tube7.31
  • Prostate6.7
  • Adrenal Gland6.45
  • Colon - Transverse6.34
  • Esophagus - Mucosa5.91
  • Kidney - Medulla5.85
  • Pituitary5.77
  • Stomach5.77

And 29 more, listed on the interactive page.

And 11 more, listed on the interactive page.

  • regulation of catalytic activity

    • biochemical: NVS_ENZ_hLynA, is one of one assay component(s) measured or calculated from the NVS_ENZ_hLynA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
    • biochemical: NVS_ENZ_hLynA, is one of one assay component(s) measured or calculated from the NVS_ENZ_hLynA assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.

    Biological samples

    • cell-free
    Evidence source
    www.epa.gov

Related records

Trials (955)

Drugs (15)